BioSpace News Archive

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on October 13, 2022, Health Canada authorized ACTEMRA® IV.

Cigna health plans will be available on the individual marketplace for Indiana residents in eight counties, giving more people and communities access to affordable, predictable, and simple health care coverage in 2023.

The Biotechnology Innovation Organization and the Council of State Bioscience Associations released new data on the bioscience industry in the United States.

Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close.

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2022.

Hinova Pharmaceuticals Inc. (STAR: 688302) today presented their preclinical results of HP518, an orally bioavailable chimeric degrader targeting androgen receptor (AR) for prostate cancer treatment, at the 5th Annual TPD Summit.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) would like to share an internal report indicating the Company’s Covid PCR (Polymerase Chain Reaction) testing has experienced a significant spike in positivity rates in their testing results in the film and production industry.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA.

Akari Therapeutics, Plc (Nasdaq: AKTX) today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before markets open.